CLINICAL OUTCOMES OF VIRAL RESPIRATORY INFECTIONS AMONG IMMUNOSUPPRESSED INDIVIDUALS

Viral respiration infections (VRIs) pose an enormous danger to immunocompromised sufferers, which includes cancer sufferers and recipients of hematopoietic stem cellular transplants, leading to high morbidity and mortality globally. These infections, because of pathogens consisting of influenza viruses, coronaviruses, respiration syncytial virus (RSV), and rhinoviruses, variety from slight top respiration tract infections to excessive lower breathing tract headaches. Immunocompromised people, along with the aged and younger children, are mainly at risk of severe results. The financial and clinical burden of VRIs is sizeable, exacerbated through demanding situations in diagnosis and management. Traditional diagnostic methods, including viral culture and serology, offer specificity but are restricted by means of gradual turnaround times and decrease sensitivity. Advances in molecular technique, including next-generation sequencing (NGS), polymerase chain reaction (PCR), and real time PCR, have revolutionized the detection of respiration viruses by providing fast, accurate and high- through put consequences. These technology enable early prognosis, essential for timely intervention and outbreak manipulate. However, demanding situations including price, technical complexity, and the need for nonstop updates to stumble on viral mutations persist. This review highlights the importance of integrating speedy screening checks with confirmatory molecular assays to stability pace and accuracy, mainly in aid - constrained settings. Emerging point of care technologies and the ability of synthetic intelligence in diagnostics ate also discussed. Strengthening global surveillance networks and improving public health guidelines are vital to mitigating the effects of VRIs. Future efforts ought to consciousness on growing low cost diagnostics, vast- spectrum antivirals, and powerful vaccines to guard vulnerable populations and decrease the world wide burden of respiratory viral infections.